Literature DB >> 31501269

Hepatitis C Virus: 30 Years after Its Discovery.

Michael Houghton1.   

Abstract

Evidence for the existence of another hepatitis-causing pathogen, other than the known hepatitis A and B viruses, emerged in the mid-1970s. A frustrating search of 15 years was ended by the identification of the hepatitis C virus in 1989 using a recombinant DNA immunoscreening method. This discovery quickly led to blood tests that eliminated posttransfusion hepatitis C and could show the partial efficacy of type 1 interferon-based therapies. Subsequent knowledge of the viral replication cycle then led to the development of effective direct-acting antivirals targeting its serine protease, polymerase, and nonstructural protein 5A that resulted in the approval of orally available drug combinations that can cure patients within a few months with few side effects. Meanwhile, vaccine strategies have been shown to be feasible, and they are still required to effectively control this global epidemic.
Copyright © 2019 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31501269      PMCID: PMC6886456          DOI: 10.1101/cshperspect.a037069

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  5 in total

1.  Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial.

Authors:  Flavio A Cadegiani; Ricardo A Zimerman; Daniel N Fonseca; Michael N Correia; Marcio P Muller; Diego Leonardo Bet; Marcio Rafael Slaviero; Ivan Zardo; Paulo Roberto Benites; Renan N Barros; Raysa W Paulain; Dirce C Onety; Karla Cristina P Israel; Carlos Gustavo Wambier; Andy Goren
Journal:  Cureus       Date:  2021-12-25

Review 2.  Role of EGF Receptor Regulatory Networks in the Host Response to Viral Infections.

Authors:  Cathleen R Carlin
Journal:  Front Cell Infect Microbiol       Date:  2022-01-10       Impact factor: 5.293

3.  Special Issue "New Therapies of Liver Diseases".

Authors:  Pierluigi Toniutto
Journal:  J Clin Med       Date:  2022-03-24       Impact factor: 4.241

Review 4.  Roles of microRNAs in Hepatitis C Virus Replication and Pathogenesis.

Authors:  Hui-Chun Li; Chee-Hing Yang; Shih-Yen Lo
Journal:  Viruses       Date:  2022-08-15       Impact factor: 5.818

Review 5.  An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection.

Authors:  Pearson Balatow; Amber Sandlin; Theodore James Cory
Journal:  Expert Opin Pharmacother       Date:  2021-07-01       Impact factor: 4.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.